Epilepsy remains a major area of focus and commitment for our internal development program at PORSOLT.

We recently validated two novel reference compounds in our Electrical Amygdala Kindling in vivo model: Retigabine and Perampanel (third generation drug), in keeping up with the most recent clinical developments and the diversity of mechanism available for treatment.
This model demonstrates good versatility in detecting potential therapeutics with varied mechanisms of action.
Please contact us for more information on our epilepsy models.

 

contact@porsolt.com
www.porsolt.com